Literature DB >> 9130043

Regulation of human cytomegalovirus immediate-early gene expression.

J L Meier1, M F Stinski.   

Abstract

The positive and negative cis-acting elements that affect transcription from the human cytomegalovirus major immediate-early (MIE) promoter and the viral and cellular proteins that bind to these elements are discussed. The data obtained using in vitro transcription and transient transfection assays are reviewed and compared to recent data using recombinant viruses with cis-acting elements deleted. The effects of cell type and cellular differentiation on activation of transcription from the MIE promoter are compared with the effects of mitogens and virion-associated tegument proteins that directly or indirectly activate protein kinase pathways. The repressor and enhancer regions upstream of the MIE promoter in the large unique component of the viral genome are compared to the elements upstream of the more simplified IEUS3 promoter in the short unique component of the viral genome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9130043     DOI: 10.1159/000150504

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  63 in total

1.  A strong negative transcriptional regulatory region between the human cytomegalovirus UL127 gene and the major immediate-early enhancer.

Authors:  C A Lundquist; J L Meier; M F Stinski
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs.

Authors:  N K Grzimek; D Dreis; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus.

Authors:  N K Grzimek; J Podlech; H P Steffens; R Holtappels; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection.

Authors:  Hiroki Isomura; Mark F Stinski
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  Role of the proximal enhancer of the major immediate-early promoter in human cytomegalovirus replication.

Authors:  Hiroki Isomura; Tatsuya Tsurumi; Mark F Stinski
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Regulation of the transcription and replication cycle of human cytomegalovirus is insensitive to genetic elimination of the cognate NF-kappaB binding sites in the enhancer.

Authors:  Montse Gustems; Eva Borst; Chris A Benedict; Carmen Pérez; Martin Messerle; Peter Ghazal; Ana Angulo
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Deletion of open reading frame UL26 from the human cytomegalovirus genome results in reduced viral growth, which involves impaired stability of viral particles.

Authors:  Kerstin Lorz; Heike Hofmann; Anja Berndt; Nina Tavalai; Regina Mueller; Ursula Schlötzer-Schrehardt; Thomas Stamminger
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 8.  Chromatin-mediated regulation of cytomegalovirus gene expression.

Authors:  Matthew B Reeves
Journal:  Virus Res       Date:  2010-09-25       Impact factor: 3.303

Review 9.  Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency.

Authors:  Mark F Stinski; Hiroki Isomura
Journal:  Med Microbiol Immunol       Date:  2007-12-19       Impact factor: 3.402

10.  Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression.

Authors:  Chih-Chuan Chang; Jonathan D Heller; Jennifer Kuo; Ru Chih C Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.